Quest Diagnostics
1,142 hedge funds and large institutions have $23.9B invested in Quest Diagnostics in 2026 Q3 according to their latest regulatory filings, with 136 funds opening new positions, 382 increasing their positions, 405 reducing their positions, and 87 closing their positions.
56% more first-time investments, than exits
New positions opened: 136 | Existing positions closed: 87
2% more funds holding
Funds holding: 1,119 → 1,142 (+23)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6% less repeat investments, than reductions
Existing positions increased: 382 | Existing positions reduced: 405
1.97% less ownership
Funds ownership: 95.01% → 93.04% (-2%)
18% less capital inflows, than outflows
Capital inflows: $1.72B | Capital outflows: $2.1B
34% less call options, than puts
Call options by funds: $93.3M | Put options by funds: $140M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$720M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$82.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$69M |
| 4 |
Goldman Sachs
New York
|
+$63.6M |
| 5 |
Squarepoint
New York
|
+$58.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$146M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$133M |
| 3 |
Woodline Partners
San Francisco,
California
|
-$111M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$98M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$96.7M |
DGX Hedge Fund Activity: Q3 2026 in Review
1,142 of the 8,220 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q3 2026, worth a combined $23.9B — up 7.5% from $22.3B a quarter earlier.
Buyers outnumbered sellers: 136 funds opened new DGX positions and 87 closed out — a net gain of 49 holders — while 382 added to existing stakes and 405 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $720M. The largest seller was JP Morgan Chase, cutting an estimated $146M.
- 1,142 institutional investors held Quest Diagnostics (DGX) as of Q3 2026, up from 1,119 in Q2 2026.
- Funds reported $23.9B of Quest Diagnostics stock for Q3 2026, up 7.5% quarter-over-quarter.
- 136 funds opened new Quest Diagnostics positions in Q3 2026 and 87 closed out, a net change of +49 holders.
- The largest Quest Diagnostics buyer in Q3 2026 was Fidelity Investments, an estimated $720M added.
- The largest Quest Diagnostics seller in Q3 2026 was JP Morgan Chase, an estimated $146M sold.
Based on aggregated 13F filings for Q3 2026.